How strong is the clinical evidence for exosome therapy?
Where exosome research sits on the evidence pyramid, what the trial registry shows, and the main limitations of the studies published so far.

Key takeaways.
- The foundation of exosome research is preclinical: laboratory and animal studies.
- Over 200 exosome trials were registered on ClinicalTrials.gov as of 2024, mostly early phase.
- Most published human studies include fewer than fifty participants, and many fewer than twenty.
- Case reports cannot establish efficacy because they have no control group.
- Small studies give uncertain effect estimates and cannot reliably detect rare harms.
- Exosomes remain investigational and are not FDA-approved for therapeutic use.
The evidence pyramid, applied to exosomes
Not all evidence carries equal weight. Animal studies show biological plausibility. Case reports and uncontrolled series give early signals but cannot separate a treatment effect from natural history, placebo response or regression to the mean.
Randomized controlled trials are the gold standard because randomization, control groups and blinding address those problems. Systematic reviews of good trials sit at the top.
Where exosomes sit today
Exosome therapy rests mainly on the lower levels. There are thousands of laboratory studies and hundreds of animal studies across cardiovascular, neurologic, wound, inflammatory and degenerative models.
Human research is growing. More than 200 trials were registered on ClinicalTrials.gov as of 2024. Most therapeutic trials are Phase I or II, designed to establish safety and look for preliminary signals. Published clinical studies include early work in severe COVID-19 lung injury and graft-versus-host disease.
Limitations to look for
Small sample size is the most pervasive limitation. Small studies lack statistical power, produce wide confidence intervals, and cannot reliably detect rare but important adverse events.
Other challenges are specific to a new biologic. Manufacturing standardization, potency assessment and optimal dosing are not fully worked out, which makes studies hard to compare.
What this means for practice
Critical appraisal is the core skill here. Commercial interest and social media can amplify preliminary findings beyond what they support.
The evidence does not yet support moving exosomes from investigational therapy to established treatment. Exosome therapies are not FDA-approved for therapeutic use.
Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.
This guide covers the what and the why.
The how is taught live. The webinar and live training go deeper on:
- Walking through the key published studies and their limits
- Ongoing trials to watch
- A framework for appraising new exosome papers
- Applying evidence grading to clinical decisions
Common questions.
Are there randomized controlled trials of exosome therapy?
How many exosome clinical trials are there?
Can I rely on case reports of exosome treatment?
Sources
- Sengupta, V., et al. (2020). Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells and Development, 29(12), 747-754.
- Kordelas, L., et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28(4), 970-973.
- Wiklander, O. P. B., et al. (2019). Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 11(492), eaav8521.
Keep reading.
Exosome · 3 min read
Challenges facing exosome therapy: standardization, manufacturing and regulation
The main obstacles between exosome research and approved products: loose terminology, hard-to-scale manufacturing, the FDA biologics pathway and open science questions.
Start the lessonExosome · 2 min read
Personalized exosome therapy: why responses vary and what biomarkers could add
Why response to exosomes appears to vary between individuals, how disease stage may matter, and what predictive biomarkers are meant to do.
Start the lessonExosome · 3 min read
Ethics of offering exosome therapy: consent, cost and marketing
The ethical ground rules for clinicians considering exosomes: informed consent for an investigational therapy, patient selection, cost, honest marketing and competency.
Start the lessonReady for the hands-on detail?
Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.